Reviewing Ginkgo Bioworks (DNA) & Its Rivals
by Sarita Garza · The Markets DailyGinkgo Bioworks (NYSE:DNA – Get Free Report) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its rivals? We will compare Ginkgo Bioworks to similar businesses based on the strength of its risk, earnings, analyst recommendations, profitability, valuation, dividends and institutional ownership.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Ginkgo Bioworks and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ginkgo Bioworks | 2 | 2 | 0 | 0 | 1.50 |
| Ginkgo Bioworks Competitors | 954 | 3181 | 5515 | 178 | 2.50 |
Ginkgo Bioworks presently has a consensus target price of $7.00, suggesting a potential downside of 42.79%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 2.29%. Given Ginkgo Bioworks’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Ginkgo Bioworks has less favorable growth aspects than its rivals.
Volatility & Risk
Ginkgo Bioworks has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks’ rivals have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.
Valuation & Earnings
This table compares Ginkgo Bioworks and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Ginkgo Bioworks | $170.15 million | -$312.76 million | -2.91 |
| Ginkgo Bioworks Competitors | $2.26 billion | $55.88 billion | -7.91 |
Ginkgo Bioworks’ rivals have higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 54.3% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Ginkgo Bioworks and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ginkgo Bioworks | -259.96% | -60.27% | -26.88% |
| Ginkgo Bioworks Competitors | -538.51% | -166.21% | -13.47% |
Summary
Ginkgo Bioworks rivals beat Ginkgo Bioworks on 8 of the 13 factors compared.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.